Pooled analysis showed that there was no significant changes of eGFR associated with SGLT2 inhibitors compared with placebo or other anti-diabetic medications (MD-0.75 ml/minutes/1.73 m2, 95% CI −1.61to 0.10, P = .09, shown in Fig. 3) in T2DM with CKD. This evidence concerns the gene SLC5A2 and chronic kidney disease.